



**Aspira Pathlab & Diagnostics Limited**  
**Registered. Office:** Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086  
**Corporate Office:** 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086  
**CIN:** L85100MH1973PLC289209

**Date: November 12, 2025**

To,  
Listing Department  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001.

**Security Code: 540788**  
**Security ID: ASPIRA**

**Sub: Outcome of Board Meeting held on Wednesday, November 12, 2025**

Dear Sir/Madam,

In compliance with the SEBI (LODR) Regulations, 2015 ("Listing Regulations") this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. on Wednesday, November 12, 2025 inter alia, has considered, approved and taken on record the following matter(s):

1. Un-Audited Standalone Financial Results along with Limited Review Report for the second quarter/half year ended September 30, 2025 ("the financial results") duly reviewed and approved by the Audit Committee and Board of Directors as per regulation 33 of the Listing Regulations is attached herewith and
2. On the recommendation of Nomination and remuneration committee, Board approved the appointment of Mrs. Kiran Raghavendra Awasthi (DIN: 09066721) as an Additional Independent Director for a First Term of five (5) years w.e.f. November 12, 2025, subject to the approval of the members of the Company.

Additional details pursuant to regulation 30 of the SEBI(LODR) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith in **Annexure-1**.

Kindly note that Board Meeting commenced at 06.15 P.M (IST) and concluded at 07.45 P.M.(IST)

The above information is being made available on the website of the Company [www.aspiradiagnostics.com](http://www.aspiradiagnostics.com).

We request you to kindly take the same on your record.

Thanking you.

Yours Faithfully,

**For and on behalf of**  
**Aspira Pathlab & Diagnostics Limited**

**Pankaj Shah**  
**Managing Director & CEO**

**INDIA'S FIRST**  
**FULLY INTEGRATED LAB**

☎ 0227197 5756, 022 2513 9090 🌐 [www.aspiradiagnostics.com](http://www.aspiradiagnostics.com)  
✉ [support@aspiradiagnostics.com](mailto:support@aspiradiagnostics.com) | [info@aspiradiagnostics.com](mailto:info@aspiradiagnostics.com)



## Aspira Pathlab & Diagnostics Limited

**Registered. Office:** Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086  
**Corporate Office:** 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086  
**CIN:** L85100MH1973PLC289209

**CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE BOARD OF DIRECTORS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED ("THE COMPANY") IN ITS MEETING HELD ON WEDNESDAY, NOVEMBER 12, 2025 COMMENCED AT 06.15 P.M (IST) AT UNIT 6 & 7, GROUND FLOOR, BHAVESHWAR ARCADE PREMISES CO-OP. SOCIETY LTD, NITYANAND NAGAR, GHATKOPAR WEST, MUMBAI-400086, MAHARASHTRA**

**AUTHORISATION FOR SIGNING OF THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE SECOND QUARTER/HALF YEAR ENDED SEPTEMBER 30, 2025**

**"RESOLVED THAT** pursuant to regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the unaudited standalone financial results for the second quarter/half year ended September 30, 2025 be and are hereby approved.

**RESOLVED FURTHER THAT** pursuant to regulation 33(2)(b) of the SEBI (LODR) Regulations, 2015, Mr. Nikunj Mange, Executive Director (DIN: 08489442) of the Company be and is hereby authorised on behalf of the Board members to sign the aforesaid unaudited standalone financial results for the second quarter/half year ended September 30, 2025".

**For and on behalf of  
Aspira Pathlab & Diagnostics Limited**

**Pankaj Shah  
Managing Director & CEO**

**ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

(CIN : L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhanand Road, Opp. Railway Station, Ghatkopar ( W), Mumbai -400086

Tel No. 022-71975756, Email :support@aspiradiagnostics.com,Website : www.aspiradiagnostics.com

**Standalone Balance Sheet as at 30 September 2025**

(Rupees in Lakhs)

Particulars	As at 30 September 2025 (un-audited)	As at 31 March 2025 (Audited)
<b>A ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	198.37	207.72
Right of Use Assets	164.97	178.42
Goodwill	305.72	265.18
Other Intangible assets	1.58	1.41
<b>Financial Assests</b>		
(i) Investments in associates	-	13.00
(ii) Loans and advances	347.91	334.59
(iii) Others	317.29	214.38
<b>Total non-current assets</b>	<b>1,335.83</b>	<b>1,214.70</b>
<b>Current Assets</b>		
Inventories	66.27	51.13
<b>Financial Assests</b>		
(i) Trade Receivables	371.35	235.16
(ii) Cash and Cash Equivalents	148.98	175.24
(iii) Bank balances other than (ii) above	39.96	39.16
(iv) Others financial assets	3.73	1.16
Current tax assets (net)	32.54	19.33
Other Current Assets	17.64	15.24
<b>Total Current Assets</b>	<b>680.47</b>	<b>536.44</b>
<b>Total Assets</b>	<b>2,016.30</b>	<b>1,751.15</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share Capital	1,029.30	1,029.30
Other equity	413.04	192.34
<b>Total Equity</b>	<b>1,442.34</b>	<b>1,221.64</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
(i) Borrowings	127.88	120.64
(ii) Lease liabilities	96.70	116.28
Provisions	63.43	55.36
<b>Total non-current liabilities</b>	<b>288.01</b>	<b>292.28</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(i) Borrowings	-	-
(ii) Lease liabilities	87.76	82.68
(iii) Trade paybles		
Total outstanding dues of micro and small enterprises		17.78
Total outstanding dues of creditors other than micro and small enterprises	102.41	56.02
(iv) Other financial liabilities	77.01	60.73
Other current liabilities	14.05	15.30
Provisions	4.73	4.73
<b>Total current liabilities</b>	<b>285.96</b>	<b>237.23</b>
<b>Total Liabilities</b>	<b>573.97</b>	<b>529.51</b>
<b>Total Equity and Liabilities</b>	<b>2,016.30</b>	<b>1,751.15</b>

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange  
Executive Director  
DIN. 08489442  
Place : Mumbai  
Date : 12.11.2025



FOR SARDA SONI ASSOCIATES LLP  
CHARTERED ACCOUNTANTS

(MANOJ KUMAR JAIN)  
PARTNER  
M. No.120788





**ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar ( W), Mumbai -400086  
Tel No. 022-71975756, Email :support@aspiradiagnostics.com,Website : www.aspiradiagnostics.com

**Statement of Standalone Financial Results for the Quarter and Six months ended 30th September, 2025**

(Rupees in Lakhs)

Particulars	Quarter ended			Six Months ended		Year ended
	30-Sep-25 (Unaudited)	30-Jun-25 (Unaudited)	30-Sep-24 (Unaudited)	30-Sep-25 (Unaudited)	30-Sep-24 (Unaudited)	31-Mar-25 (Audited)
<b>1. Income</b>						
(a) Revenue from Operations	809.28	524.80	617.76	1,334.08	1,081.49	2,199.90
(b) Other Income	13.96	10.77	7.58	24.73	16.75	38.89
<b>Total Income</b>	<b>823.23</b>	<b>535.57</b>	<b>625.33</b>	<b>1,358.80</b>	<b>1,098.24</b>	<b>2,238.79</b>
<b>2. Expenses</b>						
(a) Cost of Materials consumed	128.27	89.60	109.71	217.87	197.74	369.58
(b) Laboratory Testing Charges	33.53	27.42	26.16	60.95	52.15	99.65
(c) Employee benefits expense	214.63	189.01	175.41	403.64	341.64	732.62
(d) Finance Costs	9.76	9.40	7.89	19.17	16.01	34.74
(e) Depreciation and amortisation expense	39.55	36.52	36.39	76.08	74.05	149.38
(f) Other expenses	213.94	136.67	170.76	350.62	319.29	645.57
<b>Total Expenses</b>	<b>639.69</b>	<b>488.63</b>	<b>526.30</b>	<b>1,128.32</b>	<b>1,000.88</b>	<b>2,031.53</b>
<b>3. Profit / (Loss) before exceptional items and tax (1-2)</b>	<b>183.54</b>	<b>46.94</b>	<b>99.03</b>	<b>230.49</b>	<b>97.36</b>	<b>207.26</b>
<b>4. Exceptional Items</b>	-	-	-	-	-	-
<b>5. Profit / (Loss) before tax (3+4)</b>	<b>183.54</b>	<b>46.94</b>	<b>99.03</b>	<b>230.49</b>	<b>97.36</b>	<b>207.26</b>
<b>6. Tax Expenses</b>	-	-	-	-	-	-
<b>7. Profit / (Loss) after tax (5-6)</b>	<b>183.54</b>	<b>46.94</b>	<b>99.03</b>	<b>230.49</b>	<b>97.36</b>	<b>207.26</b>
<b>8. Other Comprehensive income (net of tax)</b>	-	-	-	-	-	0.04
<b>9. Total Comprehensive Income/ (Loss) (7+8)</b>	<b>183.54</b>	<b>46.94</b>	<b>99.03</b>	<b>230.49</b>	<b>97.36</b>	<b>207.30</b>
<b>10. Paid up Equity share capital ( face value of Rs.10 each)</b>	<b>1,029.30</b>	<b>1,029.30</b>	<b>1,029.30</b>	<b>1,029.30</b>	<b>1,029.30</b>	<b>1,029.30</b>
<b>11. Other Equity</b>	-	-	-	-	-	192.34
<b>12. Earning per share (in Rupees)</b>						
(a) Basic	1.78	0.46	0.96	2.24	0.95	2.01
(b) Diluted	1.78	0.46	0.96	2.24	0.95	2.01

**Notes**

1. The above Standalone financial results of the Company for the quarter and six months ended September 30, 2025 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 12th November, 2025.

2. The Standalone financial results for the quarter and six month ended September 30, 2025 has been subjected to limited review by statutory auditors of the Company and not subjected to audit. The auditors have expressed an unmodified opinion in the limited review report for the quarter and six months ended September 30, 2025.

3. These Standalone financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.

4. Disclosure of segment wise information is not applicable, as pathology services is the Company's only business segment.

**5. Business Acquisition and Consolidation Status:**

The Company has acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for a consideration of ₹13.00 lakhs, effective from the end of business day on 30th June 2025, pursuant to a Business Transfer Agreement. Accordingly, the results for the quarter ended 30th June 2025 do not include the operations of the said LLP, whereas the results for the quarter and half year ended 30th September 2025 include its operations from 1st July 2025 onwards.

The LLP has ceased business operations and is in the process of winding up under the LLP Act, 2008. Consequently, the Company does not have any subsidiary, associate, or joint venture as on 30th September 2025, and therefore no consolidated financial results are required to be presented from this quarter onward.

6. The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange  
Executive Director  
DIN. 08489442  
Place : Mumbai  
Date : 12.11.2025



FOR SARDA SONI ASSOCIATES LLP  
CHARTERED ACCOUNTANTS

(MANOJ KUMAR JAIN)  
PARTNER  
M. No.120788

**ASPIRA PATHLAB & DIAGNOSTICS LIMITED**


Standalone Cash flow Statement for the period ended 30th Sep 2025

(All amounts in Lakhs, unless otherwise stated)

Particulars	For the period ended 30.09.2025 (₹) (Unaudited)	For the period ended 30.09.2024 (₹) (Unaudited)
<b>A CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit/(Loss) for the year	230.49	97.36
Adjustments for:		
Interest income	(24.73)	(16.27)
Bad debts		4.18
Finance Costs	19.17	16.01
Depreciation and amortisation expenses	76.08	74.05
Profit on lease termination	1.30	
Provision for impairment of trade receivables and advances	(13.11)	13.44
<b>Operating profit before working capital changes</b>	<b>289.19</b>	<b>188.76</b>
Working capital adjustments:		
(Increase)/Decrease in Trade receivables	(124.26)	(45.30)
(Increase)/Decrease in Inventories	(17.12)	(11.13)
(Increase)/Decrease in other Non Current advances	(15.88)	(0.60)
(Increase)/Decrease in Current Assets, Loans & advances and Other non-current assets	(139.71)	17.18
(Increase)/Decrease in other Current Assets	(15.65)	(9.48)
Increase/(Decrease) in Trade payables	21.51	25.89
Increase/(Decrease) in Provisions	8.06	6.30
Increase/(Decrease) in other Current and non current Liabilities	(6.01)	0.27
Increase/(Decrease) in Other financial liabilities	15.55	5.20
<b>CASH GENERATED FROM OPERATIONS</b>	<b>15.69</b>	<b>177.09</b>
Taxes Paid ( net of refunds)	-	-
<b>NET CASH (USED IN)/ GENERATED FROM OPERATING ACTIVITIES(A)</b>	<b>15.69</b>	<b>177.09</b>
<b>B CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property , plant and equipment	(18.69)	(10.77)
Purchase of intangible assets	-	-
Net cash outflow on acquisition	(6.86)	-
(Increase)/Decrease in Investments	13.00	(13.00)
Advances given to parties	-	-
Proceeds from sale of fixed assets	-	-
Interest Received	24.73	16.27
<b>NET CASH FLOW (USED IN)/ GENERATED FROM INVESTING ACTIVITIES - (B)</b>	<b>12.18</b>	<b>(7.49)</b>
<b>C CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Repayment of long term borrowings	7.24	6.46
Repayment of short term borrowings	-	-
Principal payment of Lease Liability	(42.20)	(37.02)
Interest paid on lease liabilities	(9.16)	(7.51)
Interest paid	(10.01)	(8.49)
Premium on issue of Shares	-	-
Proceeds from issue of shares	-	-
<b>NET CASH (USED IN)/ GENERATED FROM FINANCING ACTIVITIES (C)</b>	<b>(54.13)</b>	<b>(46.57)</b>
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(26.26)	123.03
Add:Cash and Cash Equivalents at the beginning of the year	175.24	80.38
Less: Cash Credits at the beginning of the year	-	-
<b>Adjusted cash &amp; cash equivalents at the beginning of the year</b>	<b>175.24</b>	<b>80.38</b>
<b>Cash and Cash Equivalents at the end of the year</b>	<b>148.98</b>	<b>203.41</b>
Components of cash and cash equivalents comprise:		
Cash in hand	11.33	8.87
Balances with banks:		
-In Current Accounts	137.39	194.50
-In Escrow Account	0.26	0.04
-In Cash Credit Accounts	-	-
-Deposits with maturity less than 3 months	-	-
<b>Cash and Cash Equivalents in cash flow statement</b>	<b>148.98</b>	<b>203.41</b>

Note:

- 1) Cash and Cash equivalents represents cash in hand and balances with banks and Overdraft Facilities.
- 2) The above standalone Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7 Statement of Cash Flows.



FOR SARDA SONI ASSOCIATES LLP  
CHARTERED ACCOUNTANTS

(MANOJ KUMAR JAIN)  
PARTNER  
M. No.120788





3) Note on non-cash investing transactions:

The Company has acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for a consideration of ₹13.00 lakhs, effective from the end of business day on 30th June 2025, pursuant to a Business Transfer Agreement. The acquisition resulted in recognition of goodwill and intangible assets and assumption of net assets and liabilities. Since these do not involve movement of cash, they have been excluded from the Statement of Cash Flows. Only Net Cash outflow for acquisition of business of LLP has been considered in Cash Flow Statement.

4) The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

  
Nikunj Munge  
Executive Director  
DIN. 08489442  
Place : Mumbai  
Date : 12.11.2025



FOR SARDA SONI ASSOCIATES LLP  
CHARTERED ACCOUNTANTS

  
(MANOJ KUMAR JAIN)  
PARTNER  
M. No.120788





# Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

**Manoj Jain**

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Limited Review Report on Unaudited Standalone Financial Results of **Aspira Pathlab & Diagnostics Limited** for the Quarter and Half Year Ended **30th September, 2025** pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors,

**Aspira Pathlab & Diagnostics Limited**

Mumbai

## 1. Introduction


We have reviewed the accompanying Statement of **Unaudited Standalone Financial Results** of **Aspira Pathlab & Diagnostics Limited** (hereinafter referred to as "the Company") for the **quarter and half year ended 30th September, 2025** ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the **Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in **Indian Accounting Standard 34 ("Ind AS 34") – Interim Financial Reporting**, prescribed under Section 133 of the **Companies Act, 2013**, and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

## 2. Scope of Review

We conducted our review of the Statement in accordance with the **Standard on Review Engagements (SRE) 2410**, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the **Institute of Chartered Accountants of India (ICAI)**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement.

A review is limited primarily to inquiries of the Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit conducted in accordance with the **Standards on Auditing (SAs)** specified under Section 143(10) of the Act. Accordingly, we do not express an audit opinion.



11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.

Phone: 022-2269 5289 ; Mobile: 98191 65816

Email: [ssaaudit2102@gmail.com](mailto:ssaaudit2102@gmail.com) / [sardasoniassociates2102@gmail.com](mailto:sardasoniassociates2102@gmail.com)

**Nagpur (HO):** "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.

Phone: 0712-2726795, 2729471



# Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

**Manoj Jain**

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

### 3. Auditor's Conclusion

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

### 4. Emphasis of Matter

We draw attention to **Note 5** of the accompanying Statement which describes that the Company has acquired the business undertaking of *Aspira DNA Diagnostics Gujarat LLP* on a slump sale basis effective from the end of business day on **30th June, 2025**. Consequently, the said LLP has ceased business operations and is in the process of winding up under the LLP Act, 2008. Accordingly, the Company does not have any subsidiary, associate, or joint venture as on **30th September, 2025**, and hence the consolidated financial results are not required to be presented.

Our conclusion is not modified in respect of this matter.

For SARDASONI ASSOCIATES LLP

Chartered Accountants

Firm Regn. No. **117235W**

(Manoj Kumar Jain)

Partner

Membership No. 120788

UDIN: **25120788BBIEMA3463**

Place: **Mumbai**

Date: **12<sup>TH</sup> November 2025]**





**Annexure-1**

Additional details pursuant to regulation 30 of the SEBI(LODR) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. no.	Particulars	Disclosure
1.	Name of Director	Mrs. Kiran Raghavendra Awasthi (DIN: 09066721)
2.	Reason of Change-Appointment	Appointed as an Additional Independent Director of the Company.
3.	Date of appointment & term of appointment	November 11, 2025 Term of five (5) years i.e November 12, 2025 till November 11, 2030 subject to the members approval
4.	Brief Profile	Mrs. Kiran Awasthi, a Chartered Accountant with over 28 years of experience in Accounts, Finance, and Taxation and is a Senior Partner at AMRG & Associates and serves on Board of Raj Oil Mills Limited as Independent Director. She has expertise in the areas of financial management, governance, and analytical leadership, with a strong commitment to professionalism and integrity.
5.	Disclosure of relationships between Directors	Mrs. Kiran Awasthi is not related to any other Director or Key Managerial Personnel (KMP) of the Company.
6.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 regarding the Director not being debarred from holding the office by virtue of any SEBI order or any other such authority.	Mrs. Kiran Awasthi is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.